Key Companies Covered in the Global Immune Repertoire Sequencing Market Research Report by Research Nester are Agilent Technologies, Inc, Illumina, Inc., Pacific Biosciences of California, Inc, QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Takara Bio, Inc, Oxford Nanopore Technologies, Ltd, BGI Group, and Atreca Inc.
New York, July 25, 2022 (GLOBE NEWSWIRE) -- According to the World Trade Organization (WTO), the imports of finished pharmaceutical products have risen by 14% during the last 20 years, with imports worth at over USD 350 billion in 2018. There has also been steady growth in trade of pharmaceutical chemical components and active ingredients.
Research Nester has published a detailed market report on ‘Global Immune Repertoire Sequencing Market’ for the forecast period, i.e., 2022-2031 which includes the ongoing industry innovations and recent trends being adopted by the major industry players to achieve their business targets. Apart from that, the inclusive data on market size, growth rate, market revenue share, growth opportunities and challenges for the market players along with worldwide analysis on five major regions, namely, North America, Latin America, Europe, Asia Pacific and Middle East & Africa has been provided in the report.
Between the year 2010 and 2019, the figure of new drugs approved for sale rose 60% from the previous decade, reaching a peak of 59 new drugs in 2018. The global immune repertoire sequencing market is estimated to grow at a CAGR of ~6% over the forecast period. The market is anticipated to grow on the back of increasing development of novel drug owing to the extensive use of immune repertoire sequencing in biomarker discovery for a better success rate and cost-effectiveness of development of rational novel drug. Immune repertoire is the collection of individual clonotypes generated by all T and B cells in the body, sequencing the T and B cell receptor genes in the immune repertoire provides broad information about a person’s health. Therefore, increasing amount of diagnosis for immune associated problems on the account of growing prevalence of immune diseases such as cancer, and asthma, is anticipated to drive the market growth in the forecast period. According to the World Health Organization (WHO), asthma was estimated to have affected 262 million people in 2019 and resulted in 4,55,000 deaths.
Get a sample copy of the report@ https://www.researchnester.com/sample-request-3997
Moreover, the global market is also anticipated to grow during the forecast period on account of the increased focus of governments on healthcare sector, especially across the developing nations with high population. According to the World Health organization (WHO), the global health expenditure has increased to almost USD 8.3 trillion between the year 2000 and 2018, that is around 10% of the global GDP. Furthermore, increase in the import and export of pharmaceutical products worldwide is also projected to boost the global market in the upcoming future.
On the basis of geography, the global immune repertoire sequencing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the North America region is anticipated to gain the largest market share in the global market during the forecast period on the back of huge expenditure on healthcare in the region. According to the Centers for Medicare & Medicaid Services (CMS), U.S. health expenditures rose 9.7% in 2020 to USD 4.1 trillion, or USD 12,530 per capita. Also, increasing prevalence of autoimmune diseases across the region is estimated to drive the market growth. For instance, approximately 10 million US people are affected by the autoimmune diseases, that is about 3% of the US population. Moreover, presence of world’s major pharma companies in the region is also projected to boost the market growth.
For more information in the analysis of this report, visit: https://www.researchnester.com/reports/immune-repertoire-sequencing-market/3997
Moreover, the market in the Asia Pacific region is expected to witness a notable growth on the back of increasing global collaboration and foreign investment in the pharmaceutical industry in the emerging countries across the region. For instance, India's pharmaceutical industry registered a 200% rise in foreign direct investment (FDI) in 2020–2021. Along with this, increasing imports and exports of pharmaceuticals products is predicted to boost the market growth in the forecast period. For instance, the Japanese pharmaceutical drug export increased by about 16% from the year 2019 to 2020. Furthermore, technological advancement in the healthcare sector in the region is also anticipated to drive the market growth in the region during the forecast period.
The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Get a Sample PDF of Immune Repertoire Sequencing Market Report@ https://www.researchnester.com/sample-request-3997
The global immune repertoire sequencing market is segmented on the basis of application into cancer immunotherapy, biomarker discovery, autoimmune diseases, vaccine development and efficacy, transplant rejection and tolerance, infectious diseases, and others, out of which, the cancer immunotherapy segment is anticipated to hold the largest market share in the global immune repertoire sequencing market on account of increasing prevalence of cancer worldwide. According to the WHO, cancer is one of the leading causes of death worldwide, with almost 10 million deaths in 2020, or almost one in six deaths. Moreover, immunotherapy is an effective way of treatment that uses a patient's own immune system to fight against cancer. Immunotherapy may work better on the certain cancers than the other available treatments do. Cancers such as skin cancer don’t respond well to traditional treatment methods (radiation or chemotherapy) but start to heal after immunotherapy.
Moreover, on the basis of end user the market is segmented into pharmaceutical companies, research institutes, diagnostic labs, and others out of which, the pharmaceutical companies segment is predicted to garner the largest share among all other sub-segments in the market across the forecast period. This can be attributed to the huge investments by pharmaceutical industries in R&D activities to develop more effective medicinal products. According to the CBO, approximately USD 83 billion were spent on R&D by the pharmaceutical sector, in 2019. Moreover, increased number of pharma companies engaged in R&D activities to discover new medicines and to bring improvement in the existing ones, is also predicted to boost the market growth in the forecast period. For instance, around 5000 pharmaceutical companies were engaged in research and development (R&D) pipelines in 2021.
For more insights on the market share of various regions: https://www.researchnester.com/sample-request-3997
The global immune repertoire sequencing market is also segmented on the basis of product type.
Global Immune Repertoire Sequencing Market; Segmentation by Product Type.
Some of the prominent players and their company profiling mentioned in the report include are Agilent Technologies, Inc, Illumina, Inc., Pacific Biosciences of California, Inc, QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Takara Bio, Inc, Oxford Nanopore Technologies, Ltd, BGI Group, and Atreca Inc. The profiling enfolds growth opportunities, challenges, market trends, competitive analysis and positioning, along with the strategies used by them to stay ahead of their competitors.
Do You Have Any Query Or Specific Requirement? Ask to Our Expert: https://www.researchnester.com/ask-the-analyst/rep-id-3997
Explore Our Recent Related Reports:
Autoimmune Disease Drugs Market Segmentation By Drug (NSAIDs, Anti-Inflammatory, Interferons, Antihyperglycemics and Others); By Disease (Rheumatoid Arthritis, Type 1 Diabetes, Multiple Sclerosis, Psoriasis, Lupus, Inflammatory Bowel Disease and Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) – Global Demand Analysis & Opportunity Outlook 2028 Medical Dynamometer Market Segmentation By Product (Chest Dynamometer, Squeeze Dynamometer, Pinch Gauge, Spring Hand Dynamometer, Push-Pull Dynamometer, Hydraulic Hand Dynamometer And Others); By Application (Carpal Tunnel Syndrome, Nerve Injury and Tendon Injury); By End-User (Hospitals, Research & development, Diagnostic laboratories and Others) - Global Demand Analysis & Opportunity Outlook 2027 Therapeutic Drug Monitoring Market Analysis by Product (Consumables, Equipment and Others); by Technology (Immunoassays, Proteomic Technologies, Chromatography, Spectrometry, Electrophoresis and Others); by Class of Drugs (Antiepileptic, Antibiotics, Anticonvulsants, Antiarrhythmic, Antineoplastic, Bronchodilators and Others) and by End User (Hospital Labs, Private Labs and Others) – Global Demand Analysis & Opportunity Outlook 2029 Medication Dispenser Market Segmentation By Product Type (Automotive unit dose dispensers, Pharmacy-based automated dispensing systems and Ward based automated dispensing systems); By End-User (Hospital pharmacies, Nursing facilities and Mobile surgical centers) - Global Demand Analysis & Opportunity Outlook 2027 Breast Biopsy Device Market Segmentation By Biopsy Component Type (Vacuum Assisted Biopsy (VAB), Core Needle Biopsy (CNB) and Fine Needle Aspiration Biopsy (FNAB)); By Guiding Technology (MRI-Guided Biopsy, Ultrasound Guided Biopsy, Mammography Guided Stereotactic Biopsy, CT-Guided Biopsy and Others); By End-Users (Hospitals, Ambulatory Surgical Centers, Clinics, Cancer Research Organizations and Others) - Global Demand Analysis & Opportunity Outlook 2027
Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.
Contact for more Info: AJ Daniel Email: info@researchnester.com U.S. Phone: +1 646 586 9123 U.K. Phone: +44 203 608 5919
For More Update Follow: - LinkedIn | Twitter | Facebook | Xing
Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial" or the "Company") is pleased to announce all of the resolutions put to holders of common shares (the "Common Shares") of the Company (the "Shareholders") at the reconvened annual and special meeting held virtually today (the "Meeting") were passed. The Meeting was originally held on July 21, 2022, and was adjourned, without any business being considered, due to a lack of quorum. Under the by-laws of the Company and the interim order granted by the C
These companies produce the only thing that matters. Especially now.
Yahoo Finance Live anchors discuss earnings and the stock performance for Newmont Goldcorp.
(Bloomberg) -- Google co-founder Sergey Brin instructed his advisers to sell his personal investments in Elon Musk’s companies in recent months after learning that he had a brief affair with his wife, according to the Wall Street Journal.Most Read from BloombergWho Is Nicole Shanahan, Woman at Center of Musk-Brin Drama?Sergey Brin Ordered Sale of Musk Investments After Affair: WSJFed to Inflict More Pain on Economy as It Readies Big Rate HikeChina’s Gen Z Is Dejected, Underemployed and Slowing t
British Airways pilots poised to launch strike action Blow for Putin as China abandons investment in Russia The FTSE 100 rises 0.4pc Lucy Burton: The return of embittered former colleagues will poison office life Sign up here for our daily business briefing newsletter
These passive-income powerhouses, with yields ranging from 7.2% to 13.6%, have been popular buys among billionaire money managers.
Should we still trust the Fed? This bigwig has serious concerns.
Francisco Blanch, Bank of America Head of Global Commodities and Derivatives Research, joins Yahoo Finance Live to discuss global energy markets, the outlook for oil prices, and how the latest developments in the Russia-Ukraine war are affecting Europe's energy supply.
Ever since the legalization of recreational cannabis for adults in Canada nearly four years ago, I've maintained my stance that the marijuana stock market would ultimately be characterized by a select handful of big winners and scores of losers. What's important to understand is that the global cannabis market is slowly marching toward a couple of key inflection points within the next two years. My view is that Tilray Brands (NASDAQ: TLRY) arguably has the best shot within its immediate peer group of benefiting from the market's rapidly changing dynamics.
Market watchers are widely predicting that this week’s Q2 GDP print will show a contraction – which make two quarters in a row, the definition of a recession. Consumer sentiment reports have shown that John Q. Public agrees with this assessment, and has for the last couple of months, and markets bear that out. Even after a recent rally, stocks remain down 17% year-to-date on the S&P 500 and a deeper 25% on the NASDAQ. The market turndown, however, brought plenty of stocks into discount trading t
Yahoo Finance tech editor Dan Howley previews Microsoft's Q4 earnings report.
Devon Energy (DVN) could produce exceptional returns because of its solid growth attributes.
After its 20-for-1 stock split, the Google parent's stock has not traded all that well. Here's how it's setting up ahead of the earnings report.
World Wrestling Entertainment Inc. disclosed Monday that it will restate financial statements back to 2019 after uncovering $14.6 million in "unrecorded expenses" paid out by former long-time Chief Executive Vince McMahon.
Yahoo Finance Live anchors preview earnings that will be reported this week.
The board of Bank of America Corporation ( NYSE:BAC ) has announced that it will be increasing its dividend by 4.8% on...
(Bloomberg) -- Elon Musk denied he had an affair with Sergey Brin’s wife, after the Wall Street Journal reported that the liaison led the Google co-founder to order his advisers to sell his investments in Musk’s companies.Most Read from BloombergWho Is Nicole Shanahan, Woman at Center of Musk-Brin Drama?Sergey Brin Ordered Sale of Musk Investments After Affair: WSJFed to Inflict More Pain on Economy as It Readies Big Rate HikeChina’s Gen Z Is Dejected, Underemployed and Slowing the EconomyTrump
Shares of Redbox Entertainment Inc. shares were surging toward their best day on record Monday, though it wasn't immediately clear what was driving the stock move.
Markets turned down in the first six months of this year, but they’ve trended up in July. Despite Friday’s pullback, the monthly gains are solid, almost 5% on the S&P 500 and 7.5% on the NASDAQ, marking a turnaround from the long drop we saw earlier. The question investors have is, is this turnaround real, or just a temporary gain in a larger bearish trend. That remains to be seen, but either way, even if the market reverts to its bearish trend, there will be opportunities for investors - findin
Goldman Sachs on Monday picked five top stocks of ahead of their quarterly earnings, saying that it keeps a "constructive" view on the sector thanks to cash flows and valuations, among other highlights.